Ardelyx competitors

Mr. Wise became Chief Executive Officer, and joined the Company’s Board of Directors, in January 2018. Mr. Wise joined Achaogen as Chief Operating Officer in 2015 and, in February 2017 he was appointed President and Chief Operating Officer.Prior to Achaogen, Mr. Wise spent 13 years at Genentech, where he established and led the Cross BioOncology franchise as Vice President, Cross BioOncology. In this role, Mr. Wise spearheaded cross-portfolio initiatives designed to drive the $10B US BioOncology business and the company’s long-term oncology strategy. During his time at Genentech, Mr. Wise also held several other leadership positions of increasing responsibility, including Senior Director, Franchise Head and Life Cycle Leader of the Lytics franchise, with overall commercial responsibility for Genentech’s hospital-based Lytics business. He previously served as a Sales Director in BioOncology, Marketing Director in Cystic Fibrosis and Immunology, and Interactive Marketing Director where he built Genentech’s digital marketing capabilities. Prior to joining Genentech in 2002, Mr. Wise worked in consumer marketing, e-commerce and online marketing outside of the healthcare industry in leadership positions at Gap, Inc. and Webvan.

Phillip Frost is a Board Member at Ym Biosciences Inc., General Partner at Peregrine Ventures Management Ltd, and Board Member at Protalix Ltd and is based in Miami Beach, Florida. He has worked as Governor at American Stock Exchange; Board Member at COCRYSTAL PHARMA, INC.; and Chairman:Dermatology at Mount Sinai. Phillip works or has worked as TRUSTEE at Frost Nevada Investments Trust, BOARD MEMBER at Shanghai Institute for Advanced Immunochemical Studies, and BOARD MEMBER at Smithsonian Institution. He studied at University of Pennsylvania until 1957, Yeshiva University, and Albert Einstein College of Medicine until 1961.

Serial Entrepreneur experienced in high tech start ups. Twenty years of extensive knowledge in managing complex technologies and technology product development. A proven track record of conceiving and growing companies from concept to successful market entry, developing new product concepts, sourcing and managing co-development activities both in US and in China. Demonstrated success in building and leading multi-functional teams, strategic planning, and decision making. Also an inventor with 25 issued US patents and experience in developing and managing Intellectual Property. Specialties: Conceiving and developing high tech business from concept to commercial success. Team building in high tech start up companies. Integrated product development and commercialization.

Cynthia Bamdad is a CEO at Minerva Biotechnologies and is based in Boston, Massachusetts. She has worked as Director at Pharmacyclics and CSO Clinical Micro Sensors, now Genmark at Minerva Biotechnologies. Cynthia works or has worked as BOARD MEMBER at Schl of Social Science, BOARD MEMBER at Urban Affairs and Public Policy, and BOARD MEMBER at Northeastern University. She attended Harvard University between 1992 and 1997 and Northeastern University.